(Q38427103)

3 September 2017

Metformin and the risk of endometrial cancer: a case-control analysis (English)

1 reference

3 September 2017

1 reference

1 reference

Claudia Becker

1

1 reference

3 September 2017

Susan S Jick

series ordinal

2

1 reference

3 September 2017

Christoph R Meier

series ordinal

3

1 reference

3 September 2017

Michael Bodmer

series ordinal

4

1 reference

3 September 2017

language of work or name

English

0 references

publication date

20 March 2013

1 reference

3 September 2017

1 reference

3 September 2017

129

1 reference

3 September 2017

3

1 reference

3 September 2017

565-569

1 reference

3 September 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Association of Exogenous Estrogen and Endometrial Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Physical activity, sedentary behaviours, and the prevention of endometrial cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Physical activity and risk of endometrial cancer: a population-based prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Cancer Incidence in BRCA1 mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Diabetes mellitus and risk of endometrial cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Hormonal contraception and risk of endometrial cancer: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Case-control study of lifetime total physical activity and endometrial cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Alcohol consumption, cigarette smoking, and endometrial cancer risk: results from the Netherlands Cohort Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Coffee drinking and endometrial cancer risk: a metaanalysis of observational studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Insulin resistance: a significant risk factor of endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

The UK General Practice Research Database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

The general practice research database: role in pharmacovigilance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Validity of the General Practice Research Database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Clinical information for research; the use of general practice databases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Validity of diagnostic coding within the General Practice Research Database: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Validation and validity of diagnoses in the General Practice Research Database: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Use of thiazolidinediones and fracture risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Long-term metformin use is associated with decreased risk of breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Metformin and the incidence of prostate cancer in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Use of metformin and the risk of ovarian cancer: a case-control analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Diabetes and risk of endometrial cancer: a population-based prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Evaluating the association between endometrial cancer and polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Diabetes mellitus and ovarian cancer (Sweden).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Diabetes and endometrial cancer: effect modification by body weight, physical activity and hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

Are GPs under-investigating older patients presenting with symptoms of ovarian cancer? Observational study using General Practice Research Database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.009

10.1016/J.YGYNO.2013.03.009

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference